[Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].
Identifieur interne : 000361 ( PubMed/Corpus ); précédent : 000360; suivant : 000362[Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].
Auteurs : L. Yang ; H Y Xu ; Y. WangSource :
- Zhonghua zhong liu za zhi [Chinese journal of oncology] [ 0253-3766 ] ; 2020.
Abstract
With the increasing number of cases and widening geographical spread, the 2019 novel coronavirus disease (COVID-19) has been classified as one of the class B infectious diseases but prevented and controlled as class A infectious disease by the National Health Commission of China. The diagnosis and treatment of lung cancer patients have been challenged greatly because of extraordinary public health measures since the lung cancer patients are a high-risk population during the COVID-19 outbreak period. Strict protection for lung cancer patients is needed to avoid infection. Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients. This review will demonstrate how to applicate appropriate and individual management for lung cancer patients to protect them from COVID-19.
DOI: 10.3760/cma.j.cn112152-20200229-00152
PubMed: 32118394
Links to Exploration step
pubmed:32118394Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].</title><author><name sortKey="Yang, L" sort="Yang, L" uniqKey="Yang L" first="L" last="Yang">L. Yang</name><affiliation><nlm:affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, H Y" sort="Xu, H Y" uniqKey="Xu H" first="H Y" last="Xu">H Y Xu</name><affiliation><nlm:affiliation>Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Y" sort="Wang, Y" uniqKey="Wang Y" first="Y" last="Wang">Y. Wang</name><affiliation><nlm:affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32118394</idno><idno type="pmid">32118394</idno><idno type="doi">10.3760/cma.j.cn112152-20200229-00152</idno><idno type="wicri:Area/PubMed/Corpus">000361</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000361</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].</title><author><name sortKey="Yang, L" sort="Yang, L" uniqKey="Yang L" first="L" last="Yang">L. Yang</name><affiliation><nlm:affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, H Y" sort="Xu, H Y" uniqKey="Xu H" first="H Y" last="Xu">H Y Xu</name><affiliation><nlm:affiliation>Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Y" sort="Wang, Y" uniqKey="Wang Y" first="Y" last="Wang">Y. Wang</name><affiliation><nlm:affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Zhonghua zhong liu za zhi [Chinese journal of oncology]</title><idno type="ISSN">0253-3766</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With the increasing number of cases and widening geographical spread, the 2019 novel coronavirus disease (COVID-19) has been classified as one of the class B infectious diseases but prevented and controlled as class A infectious disease by the National Health Commission of China. The diagnosis and treatment of lung cancer patients have been challenged greatly because of extraordinary public health measures since the lung cancer patients are a high-risk population during the COVID-19 outbreak period. Strict protection for lung cancer patients is needed to avoid infection. Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients. This review will demonstrate how to applicate appropriate and individual management for lung cancer patients to protect them from COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32118394</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0253-3766</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>0</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Zhonghua zhong liu za zhi [Chinese journal of oncology]</Title><ISOAbbreviation>Zhonghua Zhong Liu Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].</ArticleTitle><Pagination><MedlinePgn>E006</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112152-20200229-00152</ELocationID><Abstract><AbstractText>With the increasing number of cases and widening geographical spread, the 2019 novel coronavirus disease (COVID-19) has been classified as one of the class B infectious diseases but prevented and controlled as class A infectious disease by the National Health Commission of China. The diagnosis and treatment of lung cancer patients have been challenged greatly because of extraordinary public health measures since the lung cancer patients are a high-risk population during the COVID-19 outbreak period. Strict protection for lung cancer patients is needed to avoid infection. Lung cancer patients are difficult to differentiate from patients with COVID-19 in terms of clinical symptoms, which will bring great trouble to the clinical work and physical and mental health of lung cancer patients. This review will demonstrate how to applicate appropriate and individual management for lung cancer patients to protect them from COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>H Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Zhong Liu Za Zhi</MedlineTA><NlmUniqueID>7910681</NlmUniqueID><ISSNLinking>0253-3766</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText>随着新型冠状病毒肺炎（简称新冠肺炎）病例报告的增加，国家卫生健康委员会将新冠肺炎纳入乙类传染病，按照甲类传染病进行管理。在全国各地新冠肺炎防控工作开展的同时，肺癌患者的诊疗工作在新的疫情下受到了极大的挑战。肺癌患者在新冠肺炎疫情下属于高危人群，需要严密防护，避免感染。新冠肺炎患者与肺癌患者在临床症状之间易于混淆，这将给肺癌患者的鉴别诊断以及身心健康带来极大的困扰。文章述将从不同层面阐述新冠肺炎疫情下医患如何携手，共同面对肺癌患者的精细化和个体化管理，期望这些建议能帮助肺癌患者平稳度过新冠肺炎的特殊时期。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Diagnostic and therapeutic strategy</Keyword><Keyword MajorTopicYN="N">Lung neoplasm</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32118394</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112152-20200229-00152</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000361 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000361 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32118394
|texte= [Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32118394" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |